Filing Flows › QHSLab (USAQ) › Immunotherapy Treatment Sales revenue
QHSLab (USAQ) Immunotherapy Treatment Sales revenue by quarter
QHSLab's Immunotherapy Treatment Sales revenue was $94K in Q2 2026 (second quarter 2026), +3% from Q1 2026. Over the last 7 quarters it ranged from $91K (Q1 2026) to $167K (Q4 2024).
| Quarter | Immunotherapy Treatment Sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $94K | +3% | -22% |
| Q1 2026 | $91K | -35% | -6% |
| Q4 2025 | $139K | +6% | -17% |
| Q3 2025 | $131K | +10% | — |
| Q2 2025 | $120K | +23% | — |
| Q1 2025 | $97K | -42% | — |
| Q4 2024 | $167K | — | — |
Q2 2026 at a glance
QHSLab, Q2 2026: revenue $847K (+40% year over year), operating margin 5.3%, net earnings $38K, operating cash flow −$8K. The chart follows the revenue to costs, profit and cash.
Questions
What is QHSLab's Immunotherapy Treatment Sales revenue?
QHSLab's Immunotherapy Treatment Sales revenue was $94K in Q2 2026 (second quarter 2026), +3% from Q1 2026.
How has QHSLab's Immunotherapy Treatment Sales revenue changed?
Over the last 7 quarters it ranged from $91K (Q1 2026) to $167K (Q4 2024).